pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·12h ago·1 min read
save

Labcorp snaps up MLM Medical Labs to boost laboratory footprint

Medtech and testing giant Labcorp has bought out MLM Medical Labs to help grow its geographic footprint for laboratory services.

Sep 9, 2026·read at Fierce Biotech ↗

MedTech Labcorp snaps up MLM Medical Labs to boost laboratory footprint By Ben Adams Sep 9, 2026 9:14am Labcorp merger Diagnostics MedTech Medtech and testing giant Labcorp has bought out MLM Medical Labs to help grow its geographic footprint for laboratory services. MLM Medical Labs (MLM) is a central and specialty lab provider with operations across the U.S., Germany and South Africa. Labcorp will now tap into those networks, expanding its own operations into the regions.

The deal also strengthens the company’s existing biomarker and specialty testing capabilities, Labcorp said in a statement. Most notably, the transaction adds Africa to Labcorp’s network, where MLM operates the continent's first fully CAP-accredited central laboratory. It also makes the company the only central lab provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa.

Financial details of the buyout were not made public. Related Labcorp launches DTC ‘Genetic Health Panel’ to seek out multiple diseases “Clinical trial sponsors today need scientific expertise, global reach and operational flexibility to advance increasingly complex development programs,” said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp, in a release. “MLM complements Labcorp's existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies," he continued.

"Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide.” Labcorp merger Diagnostics MedTech

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
245 words · retrieved 6m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 5h agoTyra rolls toward pivotal bladder cancer study even as midphase data deflates stockFierce Biotech
  • 5h agoFDA solidifies CDER, CBER leadership posts as commissioner confirmation awaitsFierce Biotech
  • 10h agoBeeline flies into phase 3 as oral lupus drug soars past placeboFierce Biotech
  • 10h agoEvommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 failFierce Biotech
  • 14h agoSolstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2Fierce Biotech